Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

ABSTRACT:

Background and aims

Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.

Methods

Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used to predict the outcome of corticosteroid-free biologic remission at week 52 on the testing cohort. Models were constructed using baseline data, or data through week 6 of VDZ therapy.

Results

The clinical trial included 594 subjects who received VDZ with baseline active inflammation [elevated C-reactive protein (>5 mg/L)]. Subjects with missing predictor variables (N = 120) or missing outcome data (N = 2) w

SUBMITTER: Waljee AK 

PROVIDER: S-EPMC6231370 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature